Archives: Speakers

Nicole Honigman is a proactive clinical research leader with 13+ years of experience driving Phase IIa–IV trials from feasibility through close-out across global and local settings. She currently serves as Global Study Director at AstraZeneca, where she leads cross-functional teams, oversees outsourced delivery, and steers study planning, risk‑based quality management, and inspection readiness to meet timelines, budgets, and quality standards. Previously at Alexion (AZ RDU), she led country operations and global monitoring oversight, optimizing startup, recruitment, vendor management, and CRA resourcing across complex rare disease programs. Nicole’s therapeutic expertise spans hematology, nephrology, neurology, bone metabolism, rheumatology, gastrointestinal, metabolic diseases, oncology, and infectious disease, with recent emphasis on cardiovascular trials. She is trained in project management, and recognized for disciplined TMF governance, KPI-driven performance management, and effective stakeholder communication.

Joana Claverol , is the Clinical Research Director at Barcelona Children’s Hospital Sant Joan de Déu, Spain, where she leads the clinical trials office since 2012 and the Patients engagement in research area since 2015. The Clinical Research Unit is a reference unit for pediatric patients nationally and internationally, specializing in innovative treatments for highly complex patients with rare pediatric diseases. She has more than 13 years of experience in medical and clinical research in the pharmaceutical and biotechnology industry, with special knowledge and experience in drug development and clinical trial design, and all regulatory and methodological aspects related to clinical research. She holds a postgraduate in Senior Management Program of Health Institutions by IESE Business School, a Master in Pharmaceutical Marketing by Universitat Pompeu Fabra, a Master of clinical trials at Universitat de Barcelona and a BS Degree in Biological Sciences by Universitat Autonoma de Barcelona.

Richard has been a patient advocate for 30 years, surviving two cancers and a heart emergency, plus several co-morbidities and late effects. As a patient he has participated in four interventional studies and nine others. As an Advocate he has helped design over 30 more.

Richard Chairs the UK’s Cancer Research Advocates Forum, is Vice-Chair of the European CanSERV project, and has held several other leadership roles. He works with patient groups and advocates, academics and industry, and policy-makers, funders and regulators.  

Richard helped found the AllTrials campaign and useMYdata movement, and he is the founding co-Editor-in-Chief of the Journal of Research Involvement and Engagement. His professional life included successful careers in education, journalism and local government.

Andreas Seidl has 25 years of experience in development of biosimilars and NBEs in the biopharma industry. He is Chief Scientific Officer at Formycon AG and in this role responsible for the overall scientific strategy of the company. In the management board of the company he is accountable for pre-clinical and clinical development of the biosimilar pipeline of the company as well as drug product development, bioanalytics and IP. Before joining Formycon he was from 2019 to 2022 COO at Leukocare AG/Munich. In the managing board of Leukocare he was responsible for research & development activities, intellectual property and quality management. Until 2019 he held different local and global positions at Hexal AG, Sandoz Biopharmaceuticals and Novartis in the area of development of biopharmaceuticals. In the early days of biosimilars he coordinated the pioneering analytical and pharmaceutical development activities of the first wave of biosimilars and contributed so far to the development and approval of eleven biosimilar products. He holds a Ph.D. in the area of protein analysis and mass spectrometry from the University of Constance/Germany where he also studied chemistry.

Clinical Data Strategy Advisor @ the European Institute for Innovation through Health Data

Peter Casteleyn MSc, is a Technology Director whose mantra is enabling business to work smarter. With a career of over 24 years in the pharmaceutical industry, Peter has made significant contributions across various domains, including Commercial, Supply Chain, Development and Analytics. His work places him at the forefront of technological innovation in the field as he contributed to and triggered cross-industry collaborations in the area of bridging clinical care with clinical research.

His passion for being intellectually challenged in order to create solutions, combined with his eagerness to guide and work with teams with a positive can-do mentality in order to grow, have been key elements throughout his career.

End 2024, Peter retired from Johnson & Johnson after the successful introduction of a scalable Electronic Health Records integration capability.  He firmly believes in the importance of insights from data for the health care industry supported by the interoperability of health data. He’s also a big proponent of industry wide collaboration as the key to achieve this.

Experienced Clinical Operations Director with 17 years of experience in Clinical Operations.
Establishing and managing multi-center, multi-national clinical studies across diverse therapeutic areas (including: immunology, gastroenterology, oncology, hematology, dermatology).

Rebeckha Magnusson has over 20 years of experience in Clinical Development, with a strong and diverse background across Clinical Operations, Project Management, Operational Excellence and Quality Assurance. She has held key roles in both large pharmaceutical organizations and small biotech companies, contributing to programs from early development through clinical execution.

Rebeckha is certified in Lean Six Sigma and has led multiple successful process-improvement initiatives within R&D. In addition, she has established and maintained Quality Management Systems for multiple biotech companies, supporting high-quality and efficient clinical development environments.

Dr Bernhard Glombitza, a senior leader in Clinical Operations has evolved through progressively increasing responsibilities in project and people management, beginning as a project leader in R&D and culminating in roles as Head of Clinical Operations for EMEA, APAC, and LATAM. He played a pivotal role in the successful launch of the Xarelto project, managing an interdisciplinary team of over 500 global employees, which significantly contributed to its market approval and commercial success. Transitioning into Clinical Operations, he leads large organizations with up to 1000 FTEs across 40 countries, achieving > 25% increase in productivity through innovative resource management and organizational restructuring.  Currently, he is introducing the Dynamic Shared Ownership model in Clinical Operations, empowering decentralized decision-making and optimizing talent allocation to drive impactful results.